A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC r...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrylak, D.P., Vaishampayan, U.N., Patel, K.R., Higano, C.S., Albany, C., Dawson, N.A., Mehlhaff, B.A., Quinn, D.I., Nordquist, L.T., Wagner, V.J., Siegel, J., Trandafir, L., Sartor, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985394/
https://www.ncbi.nlm.nih.gov/pubmed/33744812
http://dx.doi.org/10.1016/j.esmoop.2021.100082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985394/
https://www.ncbi.nlm.nih.gov/pubmed/33744812
http://dx.doi.org/10.1016/j.esmoop.2021.100082

Ejemplares similares